Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Reports: Baxter 1Q | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Reports: Baxter 1Q

Advate, Gammagard Liquid drive BioScience growth

By: Gil Roth

President, Pharma & Biopharma Outsourcing Association

Baxter 1Q12

1Q Revenues: $3.4 billion (+3%)

1Q Earnings: $588 million (+3%)

Comments: BioScience revenues grew 4% to $1.5 billion, driven by demand for Advate and Gammagard Liquid, while the Medical Products business was up 3% to $1.9 billion. In the BioScience unit, recombinants rose 4% to $533 million, antibody therapies were up 4% to $388 million, plasma proteins were up 3% to $316 million and regenerative medicine was up 10% to $154 million.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics